FOR IMMEDIATE
#LL2392-02
RELEASE
For fnformation:
Sue Pondrom
(619) 554-8290
(61-9) 4so-0520
RESEARCHERS & PHYSICIANS RECETVE $9.1
To Study Vascular
Disease
LA JOLLA, CALIFORNIA
Scripps
Institute
of
the
new approaches
diseases
rnillion
the
Institutes
diagnosis
such as stroke
The project,
which
be a collaborative
Clinic
Investigators
by the National
National
to
\992
I|ILLION
(TSRI) in La JoIIa,
Research Institute
been awarded $g.f
Scripps
Nov. 23,
of
attack.
is
for
effort
funded
of
and Research
Heart,
and treatment
at
Foundation
The
have
Lung and Blood
(NIH) to
of
develop
vascular
a seven-year
scientists
at
California
Hea1th
and heart
office
home
peri-od,
witl
TSRI and physicians
and the
VA Hospital
at
in
La
JoIIa.
rrThe project
research
to
into
studies
said
the
the
basic
in mice,
study's
mernber of
TSRI's
Carol
at
says the
Scripps
the
include
mechanisms of
to
principal
investigator
Committee
on Vascular
Ph.D.,
NIH Division
science
everything
and eventually
H. Letendre,
programs
excellent
will
of
cell
growth
and adhesion,
bedsiderrl
Mark Ginsberg,
M.D.,
a
Biology.
associate
director
Blood Diseases
and the
fundamental
the patientrs
program was chosen for
proposed
from
funding
quality
of
for
scientific
and Resources,
rrbecause of
investigators.rl
the
PAGE 2
I{IIJLION
$9.1
She said
Center
both
University
for
Blood
with
According
process
to
the
studies
expression
conduct
in
David J.
Harvard
cells
and in
tissue
we are
norrnally
relate
disease
to
trying
to
University;
health.
grants
receive
in
University;
cell
In
analysis,
signaling,
the
will
adhesion,
form tissue.
as structural
the
Georgia.
researchers
mechanisrns of
were
and Women's Hospital,
Stanford
Scripps
seven-year,
combine basic
vascular
and Brigham
the
such areas
Ph.D.,
of the
head a group
adhesion
molecule
of mice that
the
addition
to
l;ene
researchers
will
that
TSRI Committee on Vascular
rrmeasure the
will
genes in
diseased
have been bred
to
hurnan tissue
inappropriately
gtenes. rl
to
expression
pathogenesis
the
determine
expressedrrr
changes
improve
assemble to
rrThe inappropriate
contribute
that
and Emory University
Loskutoff,
of
these
a national
studies.
expression
the
of
centers
Research
Ginsberg,
says he will
express
to
and intracellular
clinical
Biology
fund programs
molecular
by which
part
award is
medicine
of Alabama;
investigate
GRANT
research/medical
affiliated
basic
to
and clinical
Additional
the
Scripps
project
$S0.9 rnillion
research
the
NIII
in
the
these
genes in
of human vascular
when and where these
Loskutoff
level
of
of
said.
rrWe will
expressj-on
process. rt
MORE
of
man may
disease.
Thus,
genes are
then
these
attempt
genes to
to
the
PAGE
3
UIIJIJION
$9.1
TSRI researchers
anti-thrornbotic
NIH
GRANT
will
agents.
also
Since
the
TSRI Committee
the
mechanisms and processes
bleeding
but
of
clots.
blood
pathways
that
years,
an inhibitor
that
to
plaques,
event
blood
rrThe rnolecular
of
platelet
the
next
function
Another
in
orient
current
clinical
In
diagnostic
from patients
researchers
in
to
helping
samples
both
ttto build
can better
process, rr Bernstein
be "to
in
arrest
of
formation
specific
said.
acute
the
Scripps
help
applications
to
aspects
events.
Within
Federal
Drug
tt
NIH grant
Scripps
the
basic
their
will
be
Clinic's
He said
the
Ruggeri.
block
Clinic.
the
of
an rracute
unress
will
from
surgery.
role
of
scientist
work towards
and management.rt
with
clinical
or therapies,
of
the
according
a member of
diagnosis
techniques
obtain
will
the
of
40 have arterial
tearn for
and Thoracic
and future
problems
addition
Ph.D.,
project
the
project
M.D.,
problem, rr Ruqgeri
in
approval
at
of
and werve designed
designed
involved
to
dangerous
one of
occursrrr
trials
the
M.D.,
of vascurar
crinicians
will
clinical
the
age of
we've
are
lead
have no problems
we expect
member of
Eugene Bernstein,
the
that
M. Ruggeri,
occlusion
the
platelets
that
few rnonths,
for
--
an acute
past
they
inhibitor
Administration
Division
arterj-al
research
has been interested
normally
prevent
would
atherosclerotic
involving
that
thrombosis
most people
Although
Biology,
we,ve identified
may lead
on-going
l-985, Zaverio
on Vascular
may underlie
rrOver the
continue
scripps
healthy
trials
of
understand
the
said.
UORE
new
physicians
clinic
and diseased
a library
of
vascular
human vascular
mechanisms of
tissue
tissue
the
so
di-sease
PAGE 4
phase of
Another
vessels
percent
to
that
open a blood
working
over
blocked
at
is
three
gradual
the
to
involves
six
is
on the
in
head of
noted
one of
that
La JoIIa
narrowing
months in
of
procedure
Scripps
rrunderstanding
to
Division
the
the
problem
wiIl
catherization
mechanism
cardiologist.
be Williarn
laboratory
professor
and an assistant
new strategies
how restenosis
or medications
Additional
project
researchers
Dario
Sarvetnick,
Ph.D.;
Altieri,
to
participanti
M.D.;
and Martin
happens,
prevent
will
of
it,
w€ hope to
###
design
tt Penny said.
include
Joseph Loftus,
Schwartz,
of
priorities.rl
our highest
cardiac
Clinic's
UCSD.
rrBy determining
in
30-40
angioplasty
irnportance
restenosis
of the
restenosis
by plaque.
overwhelrning
director
VA Hospital
medicine
of
problem
this
studies
who have had a balloon
vessel
is
Penny, M.D.,
the
occurs
Diseases,
restenosis
Also
clinj-cal
D. Johnson, M.D.,
Cardiovascular
Solving
the
GRANT
Restenosis
patients
of
Allen
of
NIH
patients.
angioplasty
blood
I,IILLION
S9.1
Ph.D.
TSRI
Ph.D. r. Nora
at